Physician profile
John Bick
NPI 1134253784
$790.50
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $179 · 2020: $349 · 2021: $263.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $261.38 | 2019-2021 | |
| Allergan, INC. | $208.01 | 2019-2020 | |
| Eisai INC. | $70.04 | 2020-2021 | |
| Abbvie INC. | $57.01 | 2021 | |
| Janssen Pharmaceuticals, INC | $51.50 | 2020-2021 | |
| Neuronetics, INC. | $45.63 | 2019-2020 | |
| Shire North American Group INC | $30.36 | 2019 | |
| Acadia Pharmaceuticals INC | $19.65 | 2021 | |
| Merck Sharp & Dohme LLC | $17.14 | 2019 | |
| Lundbeck LLC | $15.70 | 2020 | |
| Sunovion Pharmaceuticals INC. | $14.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Bick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.